UNSPSC 51171715: Bismuth subgallate

This classification denotes a topical anti-infective agent with the molecular formula C7H4O5.Bi.HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YIW503MI7V, chemically known as 1,3,2-benzodioxabismole-5-carboxylic acid, 2,7-dihydroxy- but generally known as bismuth subgallate, which bears US NIH Compound Identifier 16682999. European Medicines Agency schedules Bismuth subgallate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13091MIG.

As of Q4 2014, BISMUTH SUBGALLATE remains the US FDA Preferred Term for this commodity. Bismuth subgallate bears US NLM identifiers UMLS ID C0053790 and NCI Concept Code C77029. SMILES: [Bi]1(Oc2c(O1)cc(cc2O)C(=O)O)[OH2].

UNSPSC 51171715 Bismuth subgallate is a Commodity code covering a specific pharmaceutical ingredient with limited visibility in recent state and local procurement activity. The available opportunities show state and local governments purchasing pharmaceuticals and pharmaceutical services, but none explicitly reference bismuth subgallate as a line item or primary procurement focus. The three most recent solicitations tagged under this code span offender drug testing services, a pharmacy benefit exploratory RFI, and a multistate cooperative purchasing agreement for generic pharmaceuticals and OTC products—none of which center on bismuth subgallate specifically. The code appears to be either misapplied to broader pharmaceutical procurement categories, or bismuth subgallate itself sees minimal direct procurement activity at the state and local level.

The issuing bodies include county-level corrections agencies, state HHS commissions, and multistate cooperative purchasing organizations. Collin County Community Supervision and Corrections Department (Texas) posted an RFP for offender specimen collection and drug testing services due July 23, 2026, with an estimated contract value of $600,000 and a two-year term. The Texas Health and Human Services Commission issued an RFI in early April 2026 to explore direct-to-manufacturer prescription programs, representing early-stage market research rather than a formal procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administered by the Minnesota Department of Administration solicited generic pharmaceuticals and OTC products via RFP due March 26, 2026, with awards effective July 1, 2026 across participating state and local facilities in Minnesota and Oregon. Geographic activity centers on Texas and the upper Midwest (Minnesota, Oregon), but the code shows no concentration of solicitation activity specific to bismuth subgallate as a distinct commodity.